Enhabit, Inc. (EHAB) Misses Q4 EPS by 2c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P dip, trading choppy as tech stocks fall
- Brent hits lowest since before start of Iran war as more tankers exit Hormuz, easing supply
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Leerink Partners on Enhabit Home Health & Hospice (EHAB): 'Very Modest EBITDA Beat with 2025 Guidance Mostly In-Line'
March 6, 2025 1:21 PM ESTLeerink Partners analyst Whit Mayo reiterated a Market Perform rating on Enhabit Home Health & Hospice (NYSE: EHAB).
The analyst comments "Reiterate Market Perform rating. 4Q results look fine with in-line revs, a modest EBITDA beat (+2%), and 2025 guided largely in-line. Home Health again... More
Jefferies Defends Enhabit Home Health & Hospice (EHAB): 'Sell-Off Unwarranted Given Stabilizing KPIs, Defensiveness vs DC, Valuation'
March 6, 2025 1:18 PM ESTJefferies analyst Brian Tanquilut reiterated a Buy rating and $9.50 price target on Enhabit Home Health & Hospice (NYSE: EHAB)
The analyst comments "We maintain our Buy on EHAB and point to Q4 results being "good enough" (slight EBITDA beat) and FY25 guidance bracketing consensus... More
